tapebrief
MTD · Q3 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

MTD · Q4 2025 Earnings

Mettler Toledo

Reported February 5, 2026

30-second summary

Mettler closed 2025 with a clean Q4 beat — adjusted EPS $13.36 vs. $12.68–$12.88 guide, local-currency sales +5% vs. ~3% guide — and FY2025 adjusted EPS of $42.73 came in above the $42.05–$42.25 raised range. The FY2026 frame matched last quarter's qualitative indication (adj EPS $46.05–$46.70, +8–9%; LC sales ~+4%), but Q1 is guided to just ~3% LC growth and +5–7% EPS, and management explicitly does not assume market improvement in 2026. The tariff offset language softened from "fully offset incremental tariffs in 2026" to "assumes tariffs remain in effect at current levels" — a more static, defensive posture.

Headline numbers

EPS

Q4 FY2025

$13.36

Revenue

Q4 FY2025

$1.13B

+8.0% YoY

Gross margin

Q4 FY2025

59.8%

Free cash flow

Q4 FY2025

$0.19B

Operating margin

Q4 FY2025

32.1%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$1.13B+8.0%$1.03B+9.7%
EPS$13.36—$11.15+19.8%
Gross margin59.8%—59.2%+60bps
Operating margin32.1%—30.1%+200bps
Free cash flow$0.19B———

Guidance

Q4 FY2025 results beat both EPS and sales growth guidance; FY2026 guidance introduced with 8–9% EPS growth and 4% local currency sales growth, though Q1 signals deceleration.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted EPSQ4 FY2025$12.68 to $12.88$13.36+$0.48 to $0.68 above guideBeat
Local Currency Sales GrowthQ4 FY2025approximately 3%5%+2 percentage points above guideBeat
Adjusted EPSFY2025$42.05 to $42.25$42.73+$0.48 to $0.68 above guideBeat
Local Currency Sales GrowthFY2025approximately 2%3%+1 percentage point above guideBeat

New guidance

MetricPeriodGuideYoY
Adjusted EPSFY2026$46.05 to $46.70+8% to +9%
Local Currency Sales GrowthFY2026approximately 4%—
Adjusted EPSQ1 FY2026$8.60 to $8.75+5% to +7%
Local Currency Sales GrowthQ1 FY2026approximately 3%—

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Adjusted Operating Profit Margin32.1%
Local Currency Sales Growth (Q4)5%
Local Currency Sales Growth (Full Year)3%
Organic Sales Growth Excluding Acquisitions (Q4)4%

Management tone

Narrative arc: Swiss tariff shock and offset pushed to 2026 → Beat the lowered bar, tariff drag re-accelerates → Clean Q4 beat, but 2026 growth posture turns static and defensive.

The tariff offset language quietly moved from active to passive. Last quarter management said "we continue to expect to fully offset incremental tariffs cost in 2026" — a forward commitment. This quarter the framing is "our guidance assumes U.S. import tariffs as well as the impact of retaliatory tariffs from other country will remain in effect at current levels." The shift from "we will offset" to "we assume current levels persist" removes the active mitigation claim that anchored the prior FY2026 frame. The 2pp Q4 tariff step-up that landed in Q3's commentary appears to have been absorbed, but management is no longer projecting a quantified offset path.

The "no improvement assumed" posture is now a third consecutive quarter. Q2 introduced it, Q3 hardened it into the 2026 base case, and this quarter management doubled down: "our forecast does not assume a significant improvement in market conditions in 2026 versus last year" — paired with explicit hedging against positive pharma/life sciences headlines: "while we acknowledge that headlines from some end markets like life sciences have been more favorable recently, geopolitical tensions remain elevated, and we assume customers are more cautious with their investments to start the year." Management is refusing to embed any sentiment recovery into the forward guide, which is unusual relative to MTD's historical posture.

On-shoring was explicitly pushed out from near-term tailwind to 2027+ opportunity. Across 2025 management consistently referenced on-shoring/reshoring as a structural driver. This quarter's framing was blunt: "I see this for the coming years as a good opportunity, but we have not factored it in as a big growth opportunity for 2026. I think it's still very early innings." Combined with the replacement-cycle deferral that has now spanned four quarters, the two pillars of the 2026+ recovery thesis are both being pulled forward in time.

China's strategic positioning continued to fade. Q3 introduced "emerging markets outside of China are now larger than China"; this quarter management explicitly anchored China expectations lower: "sitting here today would be very comfortable if it was mid single digit." This is a meaningful downgrade from MTD's historical high-single-digit China framing and signals acceptance of a structurally lower run-rate, not a cyclical trough.

Q1 weakness is being pre-positioned as conservatism. The ~3% LC and +5–7% EPS Q1 guide undershoots the FY ~4% / +8–9% frame, and management's framing of customers being "more cautious with their investments to start the year" with "gradual" improvement throughout 2026 reads as defensive setup rather than operational confidence — a familiar pattern, but one that puts Q1 execution under the microscope.

Recurring themes management leaned on this quarter:

Tariff headwinds embedded in guidance; no recovery assumed in 2026Market caution to start year despite positive pharma headlinesProduct innovation driving market share gains (X3 X-ray, Vero pipette, automation features)Replacement cycle and on-shoring as 2027+ opportunities, not near-termService business reaching $1B milestone; significant untapped install base opportunityPricing discipline (2.5% full year, 3.5% Q1) offsetting tariff headwinds and FX

Risks management surfaced:

Tariff headwinds continuing; gross tariff costs reduced operating profit by 7% in 2025 and estimated 190 bps headwind to Q4 marginsElevated geopolitical tensions limiting customer investment confidenceSoft chemical sector demand expected to persist into Q1 2026Foreign currency headwinds (100 bps Q1, 50 bps full year operating margin impact)China market volatility despite recent stability; things can change quickly

Answers to last quarter's watch list

Q4 adjusted EPS vs. $12.68–$12.88 guide. Beat cleanly at $13.36 — $0.48–$0.68 above the range, driven by +5% LC sales (vs. ~3% guide) and operational leverage. The FY2025 close at $42.73 (above $42.05–$42.25) carries into a higher FY2026 base.
Resolved positively
Q4 core industrial growth vs. low-single-digit guide. Core industrial grew 2% organic in Q4 (7% reported including acquisitions), in line with the low-single-digit framing. Status: Resolved neutrally
Quantified 2026 tariff offset bridge. Not delivered. Management instead moved to a static "tariffs remain at current levels" assumption, which sidesteps the prior "fully offset" commitment and removes the quantified bridge investors were tracking. This is a soft retreat from last quarter's framing.
Resolved negatively
Q4 adjusted operating margin vs. ~200bps YoY decline guide. Q4 adjusted operating margin of 32.1% appears to have materially outperformed the guided decline, with pricing and LC sales beat absorbing the tariff and FX drag better than indicated.
Resolved positively
Process analytics / bioprocessing growth rate. Not specifically called out in the press release with quarter-level granularity.
Continue monitoring
Tariff rate trajectory. No further escalation disclosed; the FY2026 guide explicitly assumes current levels hold. Neutral outcome, but the upside snap-back scenario from any de-escalation remains alive.
Continue monitoring

What to watch into next quarter

Whether Q1 FY2026 adjusted EPS lands in the $8.60–$8.75 guide and LC sales hit ~3%. A miss confirms the Q1 deceleration is operational rather than conservative pre-positioning and puts the FY +8–9% EPS frame at immediate risk.

Whether the tariff narrative reverts from "current levels assumed" back to a quantified offset bridge. The retreat from the prior "fully offset" commitment is the most material tone shift; restoring the bridge on the Q1 print would reaffirm management's confidence in pricing and cost actions.

Europe product inspection durability. Management flagged product inspection as the driver of Q4 Europe outperformance; Q1 will reveal whether it was project timing or a sustained run-rate.

Q1 product-line breakdown — particularly Lab and core industrial. With Q1 LC growth guided to ~3% vs. FY ~4%, the underlying mix tells investors whether the soft start is broad-based or concentrated in one segment.

Any quantification of the pharma/life sciences pipeline. Management explicitly refused to embed favorable headlines into the 2026 guide; if orders ramp during Q1, the FY +4% LC frame becomes a low bar with optionality.

China LC growth vs. management's new "comfortable at mid-single digit" framing. Any sub-mid-single-digit print confirms the structural reset rather than a cyclical recovery path.

Sources

  1. Mettler-Toledo Q4 2025 press release (SEC 8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1037646/000103764626000008/ex-991mtd8xkq42025.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.